Products & solutions & information collection of COVID-19 vaccines, new variants of SARS-CoV-2 and efficacy evaluation solutions.

PSV validated Data Poster Download pdf download

Content index

Background:

Challenge of COVID-19 vaccine discovery & development
-- to meet accumulated mutating of SARS-CoV-2 and a long-term viral genome transcrption

Products & Procotol Collection:
Efficacy Assay/Evaluation Solutions for COVID-19 Vaccines and Therapeutic antibodies

1. Products & inf collection of SARS-COV-2 (2019nCOV) UK B.1.1.7 lineage and South Africa 501Y.V2 lineage and Brazilian P.1 lineage (B.1.1.28.1)

2. Multiple variants of Spike protein & ACE2 competition binding assay
-- (UK-B.1.1.7, South African-501Y.V2, Brazilian P.1 lineage, Trimer, N501Y, D614G,etc)

3. Multi-Variants^TM SARS-CoV2 Pseudovirus-Based Neutralization Assay System
-- (D614G, N501Y, E484K, B.1.1.7, 501Y.V2, P.1, etc.)

4. Multi-Variants^TM Codon-optimized mammalian expression vector & Adenoviral vector (Hot)
-- (D614G, N501Y, E484K, B.1.1.7, 501Y.V2, P.1, etc.)

5. 293T-ACE2 stable cell line & human ACE2 expression vectors
-- Effector cell of pseudotype virus-Based Neutralization Assay System.

6. Validated SARS-CoV-2 neutralizing antibodies
-- Benchmark COVID-19 Neutralizing antibodies

Information Collection:

1. Landscape of global COVID-19 vaccine candidates development

2. COVID-19 Guidance and information collection on the new mutant variants

3. COVID-19 News and announcements collection on the new mutant variants

4. About COVID-19 Pandemic and SARS-CoV-2 Vaccine

Reference Click to check>>

BACKGROUND

Challenge of COVID-19 vaccine discovery & development: to meet accumulated mutating of SARS-CoV-2 and a long-term viral genome transcrption

COVID-19 (Coronavirus Disease 2019) is novel viral pneumonia caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, also called 2019nCoV). The world is in midst of the COVID-19 pandemic. Effective vaccines are needed to halt the spread of the SARS-CoV-2 pandemic. Based on the data from WTO, there are 52 COVID-19 vaccines in clinical stage (Supplementary Table 1.) and 162 COVID-19 vaccine candidates in pre-clinical stage (Supplementary Table 2.) 2 mRNA vaccines, the BNT162b2 from Pfizer&BioNTech and the mRNA-1273 from Moderna, have recently been issued the emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA) for the prevention of COVID-19 in individuals 16 years of age and older.

The efficacy and safety of COVID-19 vaccine candidates need carefully investigated, from pre-clinical, clinal stage to a long time after BLA. There are 2 important items here:

Firstly, the coronavirus is kept accumulated mutating. The most important mutation occurs in SARS-CoV-2 (2019nCoV) Spike protein (SARS-CoV-2 S protein). The SARS-CoV-2 (2019nCoV) Spike mediates binding and entry into host cells and is a major target of neutralizing antibodies. Most of the COVID-19 vaccines focus on spike protein^1,4-6.

Different SARS-CoV-2 lineages with diverse Spike protein mutant variants may yield a heavy impact on the course of the pandemic^2-3. The United Kingdom (UK) has faced a rapid increase in COVID-19 cases caused by a novel SARS-COV-2 (2019nCOV) lineage, the B.1.1.7 lineage, which carries a larger than a usual number of coronavirus genetic changes^7-8, particularly in the SARS-CoV-2 spike protein（Table 1）⁷.

Table 1 | All mutations and deletions occur in COVID-19 SARS-COV-2 (2019nCOV) B.1.1.7 lineage
(Click to more details about B.1.1.7 lineage related products).

Gene	Nucleotide	Amino acid
ORF1ab	C3267T	T1001I
	C5388A	A1708D
	T6954C	I2230T
	11288-11296 deletion	SGF 3675-3677 deletion
spike	21765-21770 deletion	HV 69-70 deletion (Click to more details about HV 69-70 deletion related products)
	21991-21993 deletion	Y144 deletion
	A23063T	N501Y (Click to more details about N501Y related products)
	C23271A	A570D
	C23604A	P681H
	C23709T	T716I
	T24506G	S982A
	G24914C	D1118H
Orf8	C27972T	Q27stop
	G28048T	R52I
	A28111G	Y73C
N	28280 GAT->CTA	D3L
N	C28977T	S235F

Secondly, SARS-CoV-2 was reported to integrate into the genome, which means a stable long-term expression of transcript products of SARS-CoV-2 ⁹.

In conclusion, the Efficacy of COVID-19 vaccines and neutralized antibodies need long-term tracking, which mainly focuses on the novel spike protein mutation occurring in the new lineage variant of SARS-CoV2. The efficacy evaluation solution and tools of COVID-19 vaccines and neutralized antibodies need continually updated.

PRODUCTS & PROCOTOL COLLECTION

GeneMedi Efficacy Assay/Evaluation Solutions for COVID-19 Vaccines and Therapeutic antibodies against SARS-CoV2(2019nCoV)

To meet accumulated mutating of SARS-CoV-2, GeneMedi keeps continually developing novel solutions and tools for efficacy evaluation of COVID-19 vaccines (and neutralized antibodies) against novel mutant SARS-CoV-2 (2019nCoV) lineages. Our scientist's team takes duty in fighting against the COVID-19 pandemic with our global industrial and academic partners.

1. GeneMedi information and products collection of SARS-COV-2 (2019nCOV) UK B.1.1.7 lineage and South Africa 501Y.V2 lineage and Brazilian P.1 lineage(B.1.1.28.1)

Background Reading:
Information and products collection of SARS-COV-2 (2019nCOV) UK B.1.1.7 lineage
Information and products collection of SARS-COV-2 (2019nCOV) South Africa 501Y.V2 lineage
information and products collection of SARS-COV-2 (2019nCOV) Brazilian P.1 lineage (B.1.1.28.1)

GeneMedi pseudotyped virus (pseudovirus) of SARS-COV-2 (2019nCOV) B.1.1.7 lineage

GeneMedi pseudotyped virus (pseudovirus) of SARS-COV-2 (2019nCOV) 501Y.V2 lineage

GeneMedi pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) P.1 lineage(B.1.1.28.1, Brazilian variant)

SARS-COV-2 (2019nCOV) B.1.1.7 lineage & 501Y.V2 lineage(B.1.351) & P.1 lineage (B.1.1.28.1, Brazilian variant) of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies

GeneMedi codon-optimized spike mammalian expression vector for SARS-COV-2 (2019nCOV) B.1.1.7 lineage

GeneMedi codon-optimized spike mammalian expression vector for SARS-COV-2 (2019nCOV) South Africa 501Y.V2 lineage(B.1.351).

GeneMedi codon-optimized spike mammalian expression vector for SARS-COV-2 (2019nCOV) - P.1 lineage(B.1.1.28.1, Brazilian variant)

2. Multiple variants of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies

The Spike proteins variants that GeneMedi offer is including:

1) Multiple variants of recombinant Spike protein for Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies

2) Recombinant human ACE2 protein products

Cat No.	Antigen Name of 2019-nCoV(SARS-CoV-2)	Isotypes	Order
GMP-H-ACE2001	Recombinant human solubale ACE2 protein (soluble hACE2, extracellular hACE2, C-His)	Mammalian (human cell)
GMP-H-ACE2002	Recombinant human solubale ACE2 protein (soluble hACE2, extracellular hACE2, C-His)	Mammalian (human cell)

- Competition assay for neutralizing antibodies, peptides inhibitor and vaccines-immunized serums
Picture loading failed.

Figure. Immobilized 2019-nCoV S Protein RBD-C-His (GMP-V-2019nCoV-SRBD001) can bind 10μg/ml of Human ACE-2-Fc (GMP-H-ACE2002)

3. Multi-Variants^TM SARS-CoV2 (wildtype, D614G, N501Y, E484K, B.1.1.7 lineage, 501Y.V2 lineage, and so on) Pseudotype virus-Based Neutralization Assay System for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies (Lentiviral pseudovirus)

Protocol: GeneMedi SARS-CoV2 pseudovirus-based neutralization assay-protocol pdf download Protocol Download

4. Codon-optimized mammalian expression vector for SARS-COV-2 (2019nCOV) spike wide type & mutant variants (D614G, N501Y, E484K, B.1.1.7 lineage, 501Y.V2 lineage, and so on)

Cat No.	Gene &Vector description of 2019 nCoV	Vector	Order
GMV-V-2019nCoV-017	pGM-2019nCoV-spike protein (S protein,S1+S2)	pcDNA3.1(+)
GMV-V-2019nCoV-008	pGM-2019nCoV-spike protein (S protein,S1+S2)	pcDNA3.1(+)
GMV-V-2019nCoV-054	pGM-2019nCoV-spike D614G protein (S protein,S1+S2，D614G)	pcDNA3.1(+)
GMV-V-2019nCoV-057	pGM-2019nCoV-spike S943P protein (S protein,S1+S2，S943P)	pcDNA3.1(+)
GMV-V-2019nCoV-058	pGM-2019nCoV-spike V367F protein (S protein,S1+S2，V367F)	pcDNA3.1(+)
GMV-V-2019nCoV-059	pGM-2019nCoV-spike G476S protein (S protein,S1+S2，G476S)	pcDNA3.1(+)
GMV-V-2019nCoV-060	pGM-2019nCoV-spike V483A protein (S protein,S1+S2，V483A)	pcDNA3.1(+)
GMV-V-2019nCoV-061	pGM-2019nCoV-spike H49Y protein (S protein,S1+S2，H49Y)	pcDNA3.1(+)
GMV-V-2019nCoV-062	pGM-2019nCoV-spike Q239K protein (S protein,S1+S2，Q239K)	pcDNA3.1(+)
GMV-V-2019nCoV-063	pGM-2019nCoV-spike A831V protein (S protein,S1+S2，A831V)	pcDNA3.1(+)
GMV-V-2019nCoV-064	pGM-2019nCoV-spike P1263L protein (S protein,S1+S2，P1263L)	pcDNA3.1(+)
GMV-V-2019nCoV-065	pGM-2019nCoV-spike D839Y/N/E-D839Y protein (S protein,S1+S2，D839Y/N/E-D839Y)	pcDNA3.1(+)
GMV-V-2019nCoV-066	pGM-2019nCoV-spike D839Y/N/E-D839N protein (S protein,S1+S2，D839Y/N/E-D839N )	pcDNA3.1(+)
GMV-V-2019nCoV-067	pGM-2019nCoV-spike D839Y/N/E-D839E protein (S protein,S1+S2，D839Y/N/E-D839E)	pcDNA3.1(+)
GMV-V-2019nCoV-099	pGM-2019nCoV-Spike trimer ( P2-mutant,S1/S2 cleavage site（furin cleavage sequence)-mutant,trimerization modified)	pcDNA3.1(+)
GMV-V-2019nCoV-100	pGM-Spike of SARS-COV-2 B.1.1.7 lineage whole mutation	pcDNA3.1(+)
GMV-V-2019nCoV-101	pGM-2019nCoV-Spike(S1+S2)-RBD N501Y mutation(B.1.1.7 lineage RBD)	pcDNA3.1(+)
GMV-V-2019nCoV-102	pGM-2019nCoV-Spike(S1+S2)-S1 HV 69-70 Deletion mutation(ΔH69/ΔV70,B.1.1.7 lineage)	pcDNA3.1(+)
GMV-V-2019nCoV-107	pGM-2019nCoV-Spike(S1+S2)-E484K mutation(501Y.V2 lineage)	pcDNA3.1(+)
GMV-V-2019nCoV-109	pGM-Spike(S1+S2)RBD triple mutation of 501Y.V2 lineage(K417N, E484K and N501Y)	pcDNA3.1(+)
GMV-V-2019nCoV-111	pGM-Spike (S1+S2) whole mutation variant of SARS-CoV-2(2019nCoV) 501Y.V2 lineage	pcDNA3.1(+)

Codon-optimized viral particle (Adenovirus, Lentivirus, AAV) for SARS-COV-2 (2019nCOV) spike wide type & mutant variants (D614G, N501Y, E484K, B.1.1.7 lineage, 501Y.V2 lineage, and so on)

Cat No.	Gene &Vector description of 2019 nCoV	Vector	Reporter	Order
GMV-V-2019nCoV-051	pGMLV-2019nCoV-spike（S1+S2,C-6His）	Lentiviral vector	Zsgreen
GMV-V-2019nCoV-001	pGMLV-2019nCoV-spike（S1+S2,C-6His）	Lentiviral vector	Zsgreen
GMV-V-2019nCoV-053	Ad-2019nCoV-Spike(S1+S2,C-3FLAG）	Pre-made adenovirus	null
GMV-V-2019nCoV-047	Ad-2019nCoV-Spike(S1+S2,C-3FLAG）	Pre-made adenovirus	EGFP
GMV-V-2019nCoV-002	pGMLV-2019nCoV-S1（C-6His）	Lentiviral vector	Zsgreen
GMV-V-2019nCoV-048	Ad-2019nCoV-Spike(S1 protein,C-3FLAG）	Pre-made adenovirus	EGFP
GMV-V-2019nCoV-003	pGMLV-2019nCoV-Spike RBD（C-6His）	Lentiviral vector	Zsgreen
GMV-V-2019nCoV-007	pGMAAV-2019nCoV-Spike RBD（C-3FLAG）	AAV vector	Zsgreen
GMV-V-2019nCoV-050	AAV-2019nCoV-Spike(S protein RBD,C-3FLAG）	Pre-made AAV	Zsgreen
GMV-V-2019nCoV-049	Ad-2019nCoV-Spike(S protein RBD,C-3FLAG）	Pre-made adenovirus	EGFP
GMV-V-2019nCoV-056	Ad-2019nCoV-Spike D614G (S protein,S1+S2，D614G)	Pre-made adenovirus	null
GMV-V-2019nCoV-103	pGM-2019nCoV-Spike trimer ( P2-mutant,S1/S2 cleavage site（furin cleavage sequence)-mutant,trimerization modified)	Pre-made adenovirus	null
GMV-V-2019nCoV-104	pGM-Spike of SARS-COV-2 B.1.1.7 lineage whole mutation	Pre-made adenovirus	null
GMV-V-2019nCoV-105	Ad-2019nCoV-Spike(S1+S2)-RBD N501Y mutation(B.1.1.7 lineage RBD)	Pre-made adenovirus	null
GMV-V-2019nCoV-106	Ad-2019nCoV-Spike(S1+S2)-S1 HV 69-70 Deletion mutation(ΔH69/ΔV70,B.1.1.7 lineage)	Pre-made adenovirus	null
GMV-V-2019nCoV-108	Ad-2019nCoV-Spike(S1+S2)-E484K mutation(501Y.V2 lineage)	Pre-made adenovirus	null
GMV-V-2019nCoV-110	Ad-Spike(S1+S2)RBD triple mutation of 501Y.V2 lineage(K417N, E484K and N501Y)	Pre-made adenovirus	null
GMV-V-2019nCoV-112	Ad-Spike (S1+S2) whole mutation variant of SARS-CoV-2(2019nCoV) 501Y.V2 lineage	Pre-made adenovirus	null

5. 293T-ACE2 stable cell line & human ACE2 expression vectors: Effector cell of pseudotype virus-Based Neutralization Assay System for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies (Lentiviral pseudovirus)

Human ACE2 overexpression stable HEK293T cell lines. Catalot Number: GM-SC-293T-hACE2-01 Click here for details

**Product list: Human ACE2 expression vectors**
Cat No.	2019 nCoV related Gene	Gene &Vector description of 2019 nCoV	Vector	Reporter	Tag	codon Optimized	Order
GMV-V-2019nCoV-045	TMPRSS2	pGMLv-hTMPRSS2(C-3FLAG)	Lentiviral vector	Zsgreen	C-3FLAG	No
GMV-V-2019nCoV-041	ACE2	pGMLV-hACE2(C-3FLAG)	Lentiviral vector	Zsgreen	C-3FLAG	No
GMV-V-2019nCoV-042	ACE2	pAD-hACE2(C-3FLAG)	Pre-made Adenovirus	EGFP	C-3FLAG	No
GMV-V-2019nCoV-046	TMPRSS2	pGMLv-mtmprss2(C-3FLAG)	Lentiviral vector	Zsgreen	C-3FLAG	No
GMV-V-2019nCoV-043	ACE2	pAD-mACE2(C-3FLAG)	Pre-made Adenovirus	EGFP	C-3FLAG	No
GMV-V-2019nCoV-044	ACE2	pGMLV-mACE2(C-3FLAG)	Lentiviral vector	Zsgreen	C-3FLAG	No

**Validation of hACE2 overexpression stable HEK293T cell lines (Cat. GM-SC-293T‐hACE2-01)**

Figure. ACE2 mRNA level Validation in hACE2 overexpression stable HEK293T cell lines: Cat. GM‐SC‐293T‐hACE2‐01 (A) and the cell lines were tested as Mycoplasma free (B).

**Products list: Human ACE2 overexpression stable HEK293T cell lines**
Cat No.	2019 nCoV related Gene	Gene &Vector description of 2019 nCoV	Vector	Reporter	Tag	codon Optimized	Order
GMV-V-2019nCoV-041	ACE2	pGMLV-hACE2(C-3FLAG)	Lentiviral vector	Zsgreen	C-3FLAG	No
GMV-V-2019nCoV-042	ACE2	pAD-hACE2(C-3FLAG)	Pre-made Adenovirus	EGFP	C-3FLAG	No
GMV-V-2019nCoV-043	ACE2	pAD-mACE2(C-3FLAG)	Pre-made Adenovirus	EGFP	C-3FLAG	No
GMV-V-2019nCoV-044	ACE2	pGMLV-mACE2(C-3FLAG)	Lentiviral vector	Zsgreen	C-3FLAG	No

6. Validated SARS-CoV-2 neutralizing antibodies-benchmark COVID-19 neutralizing antibodies.

Cat No.	Antigen Name of 2019-nCoV(SARS-CoV-2)	Source (Expression Host)	Isotypes	Bioactivity validation	Order
GMP-V-2019nCoV-SnAb001	Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1)	Mammalian (human cell)	human IgG1	Validated in COVID-19 Spike protein and Spike-RBD protein binding affnity. COVID-19 related neutralizing potency is validated by 1.2019nCoV pseudotyped virus based neutralization assay in 293T-ACE2 effector cell. 2. competitively blocking the binding of ACE-2 receptor with SARS-CoV-2 Spike protein.
GMP-V-2019nCoV-SnAb002	Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgM)	Mammalian (human cell)	human IgM	Validated in COVID-19 Spike protein and Spike-RBD protein binding affnity. COVID-19 related neutralizing potency is validated by 1.2019nCoV pseudotyped virus based neutralization assay in 293T-ACE2 effector cell. 2. competitively blocking the binding of ACE-2 receptor with SARS-CoV-2 Spike protein.
GMP-V-2019nCoV-SnAb003	Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgA)	Mammalian (human cell)	human IgA	Validated in COVID-19 Spike protein and Spike-RBD protein binding affnity. COVID-19 related neutralizing potency is validated by 1.2019nCoV pseudotyped virus based neutralization assay in 293T-ACE2 effector cell. 2. competitively blocking the binding of ACE-2 receptor with SARS-CoV-2 Spike protein.
GMP-V-2019nCoV-SnAb004	Anti-2019-nCoV Spike (Spike RBD domain) mouse monoclonal neutralizing antibody (IgG1)	Mammalian (human cell)	mouse IgG1	Validated in COVID-19 Spike protein and Spike-RBD protein binding affnity. COVID-19 related neutralizing potency is validated by 1.2019nCoV pseudotyped virus based neutralization assay in 293T-ACE2 effector cell. 2. competitively blocking the binding of ACE-2 receptor with SARS-CoV-2 Spike protein.
GMP-V-2019nCoV-SnAb005	Anti-2019-nCoV Spike (Spike RBD domain) Cynomolgus monoclonal neutralizing antibody (IgG1)	Mammalian (human cell)	Cynomolgus (Non human primate, NHP) IgG1	Validated in COVID-19 Spike protein and Spike-RBD protein binding affnity. COVID-19 related neutralizing potency is validated by 1.2019nCoV pseudotyped virus based neutralization assay in 293T-ACE2 effector cell. 2. competitively blocking the binding of ACE-2 receptor with SARS-CoV-2 Spike protein.

GeneMedi-SARS-CoV-2 WT and Spike Mutation Variants Pseudovirus (PSV) Based Neutralizing
Assay with GeneMedi's anti-2019-nCoV Spike Neutralizing antibodies (Nabs)

Figure. The Pseudovirus (PSV) Based Neutralizing Assay was performed on 293T-hACE2 cells infected with GeneMedi-SARS-CoV-2 WT and Spike Mutation Variants (D614G, S943P, V367F, G476S, V483A, H49Y, Q239K, A831V, P1263L, D839Y/N/E:D839Y, D839N, D839E) Pseudovirus (PSV) under treatment of GeneMedi's anti-2019-nCoV Spike Neutralizing antibodies (Nabs) . Inhibition rate was determined by comparing the relative RFP+GFP+/GFP+ rate.

GeneMedi's anti-2019-nCoV Spike Neutralizing antibodies (Nabs) and Spike RBD protein binding validation

Cat No.	Product	EC50 (ng/ml)
GMP-V-2019nCoV-SnAb001	Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1)	5
GMP-V-2019nCoV-SnAb002	Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgM)	18
GMP-V-2019nCoV-SnAb003	Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgA)	410
GMP-V-2019nCoV-SnAb004	Anti-2019-nCoV Spike (Spike RBD domain) mouse monoclonal neutralizing antibody (IgG1)	6.8
GMP-V-2019nCoV-SnAb005	Anti-2019-nCoV Spike (Spike RBD domain) Cynomolgus monoclonal neutralizing antibody (IgG1)	28

Figure. The binding of GeneMedi's anti-2019-nCoV Spike Neutralizing antibodies (Nabs) to Recombinant 2019-nCoV(SARS-CoV-2) Spike RBD protein (GMP-V-2019nCoV-SRBD001) at 5.0ug/ml (100uL/well) was measured by ELISA.

A.GMP-V-2019nCoV-SnAb001:Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1)
B.GMP-V-2019nCoV-SnAb002:Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgM)
C.GMP-V-2019nCoV-SnAb003:Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgA)
D.GMP-V-2019nCoV-SnAb004:Anti-2019-nCoV Spike (Spike RBD domain) mouse monoclonal neutralizing antibody (IgG1)
E.GMP-V-2019nCoV-SnAb005:Anti-2019-nCoV Spike (Spike RBD domain) Cynomolgus monoclonal neutralizing antibody (IgG1)

GeneMedi's anti-2019-nCoV Spike Neutralizing antibodies (Nabs) competitive binding assay validation

Cat No.	Product	IC50 (ng/ml)
GMP-V-2019nCoV-SnAb001	Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1)	26.3
GMP-V-2019nCoV-SnAb002	Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgM)	84.2
GMP-V-2019nCoV-SnAb003	Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgA)	20.5
GMP-V-2019nCoV-SnAb004	Anti-2019-nCoV Spike (Spike RBD domain) mouse monoclonal neutralizing antibody (IgG1)	81.9
GMP-V-2019nCoV-SnAb005	Anti-2019-nCoV Spike (Spike RBD domain) Cynomolgus monoclonal neutralizing antibody (IgG1)	243

Figure. GeneMedi's anti-2019-nCoV Spike Neutralizing antibodies (Nabs) block Recombinant 2019-nCoV(SARS-CoV-2) Spike RBD protein (GMP-V-2019nCoV-SRBD001) and hACE2 (GMP-H-ACE2002) binding.

A.GMP-V-2019nCoV-SnAb001:Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1)
B.GMP-V-2019nCoV-SnAb002:Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgM)
C.GMP-V-2019nCoV-SnAb003:Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgA)
D.GMP-V-2019nCoV-SnAb004:Anti-2019-nCoV Spike (Spike RBD domain) mouse monoclonal neutralizing antibody (IgG1)
E.GMP-V-2019nCoV-SnAb005:Anti-2019-nCoV Spike (Spike RBD domain) Cynomolgus monoclonal neutralizing antibody (IgG1)

GeneMedi's efficacy evaluation solutions will be useful for your anti-COVID-19 candidates funtional assay and evaluation,which is including:
1) Types of Vaccines (by testing immunized serum from human, mouse, NHP etc.)
2) Neutralizing antibodies
3) Peptides blockers (peptide inhibitors)
4) Compounds targeting Spike induced cell-fusion.

INFORMATION COLLECTION

1. Landscape of global COVID-19 vaccine candidates development

**Supplementary Table 1. 162 candidate vaccines in preclinical evaluation**
Platform	Type of candidate vaccine			Developer					Coronavirus target		Current stage of clinical evaluation/regulatory status- Coronavirus candidate				Same platform for non-Coronavirus candidates

DNA

DNA plasmids containing S-gene

Biosun Pharmed

SARS-CoV2

Pre-Clinical

DNA

DNA plasmid vaccine

Globe Biotech Limited, Bangladesh

SARS-CoV2

Pre-Clinical

DNA

Plasmid DNA, nanostructured RBD

National institute of Chemistry, Slovenia

SARS-CoV2

Pre-Clinical

DNA

DNA, engineered vaccine inserts compatible
with multiple delivery systems

DIOSynVax Ltd / University of Cambridge

SARS-CoV-2 and
Sarbeco-CoV

Pre-Clinical

DNA

DNA vaccine

Ege University

SARS-CoV2

Pre-Clinical

DNA

DNA plasmid vaccine RBD&N

Scancell/University of Nottingham/ Nottingham Trent University

SARS-CoV2

Pre-Clinical

DNA

DNA plasmid vaccine S,S1,S2,RBD &N

National Research Centre, Egypt

SARS-CoV2

Pre-Clinical

DNA

DNA with electroporation

Karolinska Institute / Cobra Biologics
(OPENCORONA Project)

SARS-CoV2

Pre-Clinical

DNA

DNA with electroporation

Chula Vaccine Research Center

SARS-CoV2

Pre-Clinical

DNA

Takis/Applied DNA Sciences/Evvivax

SARS-CoV2

Pre-Clinical

DNA

Plasmid DNA, Needle-Free Delivery

Immunomic Therapeutics, Inc./EpiVax, Inc./PharmaJet

SARS-CoV2

Pre-Clinical

SARS

DNA

DNA vaccine

BioNet Asia

SARS-CoV2

Pre-Clinical

DNA

msDNA vaccine

Mediphage Bioceuticals/University of Waterloo

SARS-CoV2

Pre-Clinical

DNA

DNA vaccine

Entos Pharmaceuticals

SARS-CoV2

Pre-Clinical

Inactivated

Inactivated + Alum

Shifa Pharmed

SARS-CoV2

Pre-Clinical

Inactivated

Milad Pharmaceutics Co.

SARS-CoV2

Pre-Clinical

MMR, IPV

Inactivated

Zista Kian Azma Co.

SARS-CoV2

Pre-Clinical

MMR, IPV

Inactivated

Kocak Farma Ilac ve Kimya San. A.S.

SARS-CoV2

Pre-Clinical

Inactivated

Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) +
CpG 1018

Institute of Vaccines and Medical Biologicals (IVAC; Vietnam) / Dynavax
/ PATH

SARS-CoV2

Pre-Clinical

Inactivated

Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) +
CpG 1018

Government Pharmaceutical Organization (GPO; Thailand) / Dynavax / PATH

SARS-CoV2

Pre-Clinical

Inactivated

Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) +
CpG 1018

Institute Butantan (Brazil) / Dynavax / PATH

SARS-CoV-2

Pre-clinical

Inactivated

Inactivated + alum

KM Biologics

SARS-CoV2

Pre-Clinical

JE, Zika

Inactivated

Selcuk University

SARS-CoV2

Pre-Clinical

Inactivated

Erciyes University

SARS-CoV2

Pre-Clinical

Inactivated

Inactivated whole virus

National Research Centre, Egypt

SARS-CoV2

Pre-Clinical

Inactivated

SARS-CoV2

Pre-Clinical

Inactivated

TBD

Osaka University/ BIKEN/ NIBIOHN

SARS-CoV2

Pre-Clinical

Inactivated

Inactivated + CpG 1018

Sinovac/Dynavax

SARS-CoV2

Pre-Clinical

Inactivated

Inactivated + CpG 1018

Valneva/Dynavax

SARS-CoV2

Pre-Clinical

Live Attenuated Virus

Codon deoptimized live attenuated vaccines

Mehmet Ali Aydinlar University / Acıbadem Labmed Health Services
A.S.

SARS-CoV2

Pre-Clinical

Live Attenuated Virus

Codon deoptimized live attenuated vaccines

Indian Immunologicals Ltd/Griffith University

SARS-CoV2

Pre-Clinical

Non Replicating Viral Vector

Ad 5 vector for intranasal administration

University of Helsinki & University of Eastern Finland

SARS-CoV2

Pre-Clinical

Non Replicating Viral Vector

Adenovirus Type 5 Vector

Globe Biotech Limited, Bangladesh

SARS-CoV2

Pre-Clinical

Non-Replicating Viral Vector

Sendai virus vector

ID Pharma

SARS-CoV2

Pre-Clinical

Non-Replicating Viral Vector

Adenovirus-based

Ankara University

SARS-CoV2

Pre-Clinical

Non-Replicating Viral Vector

Adeno-associated virus vector (AAVCOVID)

Massachusetts Eye and Ear/Massachusetts General Hospital/AveXis

SARS-CoV2

Pre-Clinical

Non-Replicating Viral Vector

MVA encoded VLP

GeoVax/BravoVax

SARS-CoV2

Pre-Clinical

LASV, EBOV, MARV, HIV

Non-replicating viral vector

MVA-S encoded

DZIF – German Center for Infection Research/IDT Biologika GmbH

SARS-CoV2

Pre-clinical

Many

Non-replicating viral vector

MVA-S

IDIBAPS-Hospital Clinic, Spain

SARS-CoV2

Pre-clinical

Non-Replicating Viral Vector

Intranasal Ad5 vaccine encoding RBD

Altimmune, Inc.

SARS-CoV2

IND filed

Influenza (NasoVAX), Anthrax
(NasoShield)

Non-Replicating Viral Vector

Adeno5-based

Erciyes University

SARS-CoV2

Pre-Clinical

Non-Replicating Viral Vector

Ad5 S (GREVAX™ platform)

Greffex

SARS-CoV2

Pre-Clinical

MERS

Non-Replicating Viral Vector

Oral Ad5 S

Stabilitech Biopharma Ltd

SARS-CoV2

Pre-Clinical

Zika, VZV, HSV-2 and Norovirus

Non-Replicating Viral Vector

adenovirus-based + HLA-matched peptides

Valo Therapeutics Ltd

Pan-Corona

Pre-Clinical

Non-Replicating Viral Vector

Vaxart

SARS-CoV2

Pre-Clinical

InfA, CHIKV, LASV, NORV; EBOV, RVF, HBV, VEE

Non-Replicating Viral Vector

MVA expressing structural proteins

Centro Nacional Biotecnología (CNB-CSIC), Spain

SARS-CoV2

Pre-Clinical

Multiple candidates

Non-Replicating Viral Vector

parainfluenza virus 5 (PIV5)-based vaccine
expressing the spike protein

University of Georgia/University of Iowa

SARS-CoV2

Pre-Clinical

MERS

Non-Replicating Viral Vector

Recombinant deactivated rabies virus
containing S1

Bharat Biotech/Thomas Jefferson University

SARS-CoV2

Pre-Clinical

HeV, NiV, EBOV, LASSA, CCHFV, MERS

Non-Replicating Viral Vector

Influenza A H1N1 vector

National Research Centre, Egypt

SARS-CoV2

Pre-Clinical

Non-Replicating Viral Vector

Newcastle disease virus expressing S

Icahn School of Medicine at Mount Sinai

SARS-CoV2

Pre-Clinical

Protein Subunit

Recombinant spike with adjuvant

Iran

SARS-CoV2

Pre-Clinical

Multiple candidates

Protein Subunit

Recombinant S protein produced in BEVS

Tampere University

SARS-CoV2

Pre-Clinical

Protein Subunit

RBD protein delivered in mannose-
conjugated chitosan nanoparticle

Ohio State University / Kazakh National Agrarian University

SARS-CoV2

Pre-Clinical

Protein Subunit

Recombinant spike protein with Essai O/W
1849101 adjuvant

Kazakh National Agrarian University

SARS-CoV2

Pre-Clinical

Protein Subunit

Peptides

Neo7Logic

SARS-CoV2

Pre-Clinical

Protein Subunit

Recombinant spike protein with Essai O/W
1849101 adjuvant

Kazakh National Agrarian University, Kazakhstan / National Scientific
Center for Especially Dangerous Infections

SARS-CoV2

Pre-Clinical

Protein Subunit

Recombinant S protein

Max-Planck-Institute of Colloids and Interfaces

SARS-CoV2

Pre-Clinical

Protein Subunit

RBD protein (baculovirus production) + FAR-
Squalene adjuvant

Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana
Cayetano Heredia (UPCH)

SARS-CoV2

Pre-Clinical

Protein Subunit

Research Institute for Biological Safety Problems, Rep of Kazakhstan

SARS-CoV2

Pre-Clinical

Protein Subunit

RBD-protein

Mynvax

SARS-CoV2

Pre-Clinical

Protein Subunit

Recombinant S protein

Izmir Biomedicine and Genome Center

SARS-CoV2

Pre-Clinical

Protein Subunit

Peptide + novel adjuvant

Bogazici University

SARS-CoV2

Pre-Clinical

Protein Subunit

S subunit intranasal liposomal formulation
with GLA/3M052 adjs.

University of Virginia

SARS-CoV2

Pre-Clinical

Protein Subunit

S-Protein (Subunit) + Adjuvant, E coli based
Expression

Helix Biogen Consult, Ogbomoso & Trinity Immonoefficient Laboratory,
Ogbomoso, Oyo State, Nigeria.

SARS-CoV2

Pre-Clinical

Protein Subunit

Protein Subunit S,N,M&S1 protein

National Research Centre, Egypt

SARS-CoV2

Pre-Clinical

Protein Subunit

University of San Martin and CONICET, Argentina

SARS-CoV2

Pre-Clinical

Protein Subunit

RBD protein fused with Fc of IgG + Adj.

Chulalongkorn University/GPO, Thailand

SARS-CoV2

Pre-Clinical

Protein Subunit

Capsid-like Particle

AdaptVac (PREVENT-nCoV consortium)

SARS-CoV2

Pre-Clinical

Protein Subunit

Drosophila S2 insect cell expression system
VLPs

ExpreS2ion

SARS-CoV2

Pre-Clinical

Protein Subunit

Peptide antigens formulated in LNP

IMV Inc

SARS-CoV2

Pre-Clinical

Protein Subunit

S protein

WRAIR/USAMRIID

SARS-CoV2

Pre-Clinical

Protein Subunit

S protein +Adjuvant

National Institute of Infectious Disease, Japan/Shionogi/UMN Pharma

SARS-CoV2

Pre-Clinical

Influenza

Protein Subunit

VLP-recombinant protein + Adjuvant

Osaka University/ BIKEN/ National Institutes of Biomedical Innovation,
Japan

SARS-CoV2

Pre-Clinical

Protein Subunit

microneedle arrays S1 subunit

Univ. of Pittsburgh

SARS-CoV2

Pre-Clinical

MERS

Protein Subunit

Peptide

Vaxil Bio

SARS-CoV2

Pre-Clinical

Protein Subunit

Peptide

Flow Pharma Inc

SARS-CoV2

Pre-Clinical

Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, BreastCA
vaccine

Protein Subunit

S protein

AJ Vaccines

SARS-CoV2

Pre-Clinical

Protein Subunit

Ii-Key peptide

Generex/EpiVax

SARS-CoV2

Pre-Clinical

Influenza, HIV, SARS-CoV

Protein Subunit

S protein

EpiVax/Univ. of Georgia

SARS-CoV2

Pre-Clinical

H7N9

Protein Subunit

Protein Subunit EPV-CoV-19

EpiVax

SARS-CoV2

Pre-Clinical

Protein Subunit

gp-96 backbone

Heat Biologics/Univ. Of Miami

SARS-CoV2

Pre-Clinical

NSCLC, HIV, malaria, Zika

Protein Subunit

Subunit vaccine

FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo

SARS-CoV2

Pre-Clinical

Protein Subunit

S1 or RBD protein

Baylor College of Medicine

SARS-CoV2

Pre-Clinical

SARS

Protein Subunit

Subunit protein, plant produced

iBio/CC-Pharming

SARS-CoV2

Pre-Clinical

Protein Subunit

Recombinant protein, nanoparticles (based
on S-protein and other epitopes)

Saint-Petersburg scientific research institute of vaccines and serums

SARS-CoV2

Pre-Clinical

Protein Subunit

COVID-19 XWG-03
truncated S (spike) proteins

Innovax/Xiamen Univ./GSK

SARS-CoV2

Pre-Clinical

HPV

Protein Subunit

Adjuvanted microsphere peptide

VIDO-InterVac, University of Saskatchewan

SARS-CoV2

Pre-Clinical

Protein Subunit

Synthetic Long Peptide Vaccine candidate for
S and M proteins

OncoGen

SARS-CoV2

Pre-Clinical

Protein Subunit

Oral E. coli-based protein expression system
of S and N proteins

MIGAL Galilee Research Institute

SARS-CoV2

Pre-Clinical

Protein Subunit

Nanoparticle vaccine

LakePharma, Inc.

SARS-CoV2

Pre-Clinical

Protein Subunit

Plant-based subunit
(RBD-Fc + Adjuvant)

Baiya Phytopharm/ Chula Vaccine Research Center

SARS-CoV2

Pre-Clinical

Protein Subunit

OMV-based vaccine

Quadram Institute Biosciences

SARS-CoV2

Pre-Clinical

Flu A, plague

Protein Subunit

OMV-based vaccine

BiOMViS Srl/Univ. of Trento

SARS-CoV2

Pre-Clinical

Protein subunit

structurally modified spherical particles of
the tobacco mosaic virus (TMV)

Lomonosov Moscow State University

SARS-CoV2

Pre-Clinical

rubella, rotavirus

Protein Subunit

Spike-based

University of Alberta

SARS-CoV2

Pre-Clinical

Hepatitis C

Protein Subunit

Recombinant S1-Fc fusion protein

AnyGo Technology

SARS-CoV2

Pre-Clinical

Protein Subunit

Recombinant protein

Yisheng Biopharma

SARS-CoV2

Pre-Clinical

Protein Subunit

Recombinant S protein in IC-BEVS

Vabiotech

SARS-CoV2

Pre-Clinical

Protein Subunit

Orally delivered, heat stable subunit

Applied Biotechnology Institute, Inc.

SARS-CoV2

Pre-Clinical

Protein Subunit

Peptides derived from Spike protein

Axon Neuroscience SE

SARS-CoV2

Pre-Clinical

Protein Subunit

MOGAM Institute for Biomedical Research, GC Pharma

SARS-CoV2

Pre-Clinical

Protein Subunit

RBD-based

Neovii/Tel Aviv University

SARS-CoV2

Pre-Clinical

Protein Subunit

Outer Membrane Vesicle (OMV)-subunit

Intravacc/Epivax

SARS-CoV2

Pre-Clinical

Protein Subunit

Outer Membrane Vesicle(OMV)-peptide

Intravacc/Epivax

SARS-CoV2

Pre-Clinical

Protein Subunit

Spike-based (epitope screening)

ImmunoPrecise/LiteVax BV

SARS-CoV2

Pre-Clinical

Protein Subunit

Spiked-based

Nanografi Nano Technology, Middle East Technical University, Ankara
University,

SARS-CoV2

Pre-Clinical

Replicating Bacteria Vector

Oral Salmonella enteritidis (3934Vac) based
protein expression system of RBD

Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana
Cayetano Heredia (UPCH)

SARS-CoV2

Pre-Clinical

Replicating Viral Vector

Intranasal Newcastle disease virus vector
(rNDV-FARVET) expressing RBD

Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana
Cayetano Heredia (UPCH)

SARS-CoV2

Pre-Clinical

Replicating Viral Vector

YF17D Vector

KU Leuven

SARS-CoV2

Pre-Clinical

Replicating Viral Vector

Measles Vector

Cadila Healthcare Limited

SARS-CoV2

Pre-Clinical

Replicating Viral Vector

Measles Vector

FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo

SARS-CoV2

Pre-Clinical

Replicating Viral Vector

Measles Virus (S, N targets)

DZIF – German Center for Infection Research/CanVirex AG

SARS-CoV2

Pre-clinical

Zika, H7N9, CHIKV

Replicating Viral Vector

Horsepox vector expressing S protein

Tonix Pharma/Southern Research

SARS-CoV2

Pre-Clinical

Smallpox, monkeypox

Replicating Viral Vector

Live viral vectored vaccine based on attenuated influenza virus backbone (intranasal)

BiOCAD and IEM

SARS-CoV2

Pre-Clinical

Influenza

Replicating Viral Vector

Recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 (intranasal)

FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo

SARS-CoV2

Pre-Clinical

Influenza

Replicating Viral Vector

Attenuated Influenza expressing
an antigenic portion of the Spike protein

Fundação Oswaldo Cruz and Instituto Buntantan

SARS-CoV2

Pre-Clinical

Influenza

Replicating Viral Vector

Influenza vector expressing RBD

University of Hong Kong

SARS-CoV2

Pre-Clinical

Replicating Viral Vector

Replicating VSV vector-based DC-targeting

University of Manitoba

SARS-CoV2

Pre-Clinical

Replicating Viral Vector

VSV-S

University of Western Ontario

SARS-CoV2

Pre-Clinical

HIV, MERS

Replicating Viral Vector

VSV-S

Aurobindo

SARS-CoV2

Pre-Clinical

Replicating Viral Vector

VSV vector

FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo

SARS-CoV2

Pre-Clinical

Replicating Viral Vector

M2-deficient single replication (M2SR)
influenza vector

UW–Madison/FluGen/Bharat Biotech

SARS-CoV2

Pre-Clinical

influenza

Replicating Viral Vector

Newcastle disease virus vector (NDV-SARS-
CoV-2/Spike)

Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.

SARS-CoV2

Pre-Clinical

Replicating Viral Vector

Avian paramyxovirus vector (APMV)

The Lancaster University, UK

SARS-CoV2

Pre-Clinical

RNA

mRNA

Providence Therapeutics

SARS-CoV2

Pre-Clinical

RNA

mRNA

Cell Tech Pharmed

SARS-CoV2

Pre-Clinical

RNA

mRNA

ReNAP Co.

SARS-CoV2

Pre-Clinical

RNA

D614G variant LNP-encapsulated mRNA

Globe Biotech Ltd

SARS-CoV2

Pre-Clinical

RNA

saRNA formulated in a NLC

Infectious Disease Research Institute/ Amyris, Inc.

SARS-CoV2

Pre-Clinical

RNA

LNP-encapsulated mRNA encoding S

Max-Planck-Institute of Colloids and Interfaces

SARS-CoV2

Pre-Clinical

RNA

Self-amplifying RNA

Gennova

SARS-CoV2

Pre-Clinical

RNA

mRNA

Selcuk University

SARS-CoV2

Pre-Clinical

RNA

LNP-mRNA

Translate Bio/Sanofi Pasteur

SARS-CoV2

Pre-Clinical

RNA

LNP-mRNA

CanSino Biologics/Precision NanoSystems

SARS-CoV2

Pre-Clinical

RNA

LNP-encapsulated mRNA cocktail encoding
VLP

Fudan University/ Shanghai JiaoTong University/RNACure Biopharma

SARS-CoV2

Pre-Clinical

RNA

LNP-encapsulated mRNA encoding RBD

Fudan University/ Shanghai JiaoTong University/RNACure Biopharma

SARS-CoV2

Pre-Clinical

RNA

Replicating Defective SARS-CoV-2 derived
RNAs

Centro Nacional Biotecnología (CNB-CSIC), Spain

SARS-CoV2

Pre-Clinical

RNA

LNP-encapsulated mRNA

University of Tokyo/ Daiichi-Sankyo

SARS-CoV2

Pre-Clinical

MERS

RNA

Liposome-encapsulated mRNA

BIOCAD

SARS-CoV2

Pre-Clinical

RNA

Several mRNA candidates

RNAimmune, Inc.

SARS-CoV2

Pre-Clinical

RNA

mRNA

FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo

SARS-CoV2

Pre-Clinical

RNA

mRNA

China CDC/Tongji University/Stermina

SARS-CoV2

Pre-Clinical

RNA

LNP-mRNA

Chula Vaccine Research Center/University of Pennsylvania

SARS-CoV2

Pre-Clinical

RNA

mRNA in an intranasal delivery system

eTheRNA

SARS-CoV2

Pre-Clinical

RNA

mRNA

Greenlight Biosciences

SARS-CoV2

Pre-Clinical

RNA

mRNA

IDIBAPS-Hospital Clinic, Spain

SARS-CoV2

Pre-Clinical

T-cell based

CD8 T cell peptide targeting (S, M, N) and
(NSPs) SARS-CoV-2 proteins

OSE immunotherapeutics

SARS-CoV2

Pre-Clinical

VLP

Plant derived VLP

Shiraz University

SARS-CoV2

Pre-Clinical

VLP

VLPs produced in BEVS

Tampere University

SARS-CoV2

Pre-Clinical

VLP

Max Planck Institute for Dynamics of Complex Technical Systems

SARS-CoV2

Pre-Clinical

VLP

Virus-like particle-based Dendritic Cell(DC)-
targeting vaccine

University of Manitoba

SARS-CoV2

Pre-Clinical

VLP

Bezmialem Vakif University

SARS-CoV2

Pre-Clinical

VLP

Middle East Technical University

SARS-CoV2

Pre-Clinical

VLP

Enveloped Virus-Like Particle (eVLP)

VBI Vaccines Inc.

SARS-CoV-2,
SARS-CoV,
MERS-CoV

Pre-Clinical

CMV, GBM, Zika

VLP

S protein integrated in HIV VLPs

IrsiCaixa AIDS Research/IRTA-CReSA/Barcelona Supercomputing
Centre/Grifols

SARS-CoV2

Pre-Clinical

VLP

VLP + Adjuvant

Mahidol University/ The Government Pharmaceutical Organization
(GPO)/Siriraj Hospital

SARS-CoV2

Pre-Clinical

VLP

Virus-like particles, lentivirus and
baculovirus vehicles

Navarrabiomed, Oncoimmunology group

SARS-CoV2

Pre-Clinical

VLP

Virus-like particle, based on RBD displayed
on virus-like particles

Saiba GmbH

SARS-CoV2

Pre-Clinical

VLP

ADDomerTM multiepitope display

Imophoron Ltd and Bristol University’s Max Planck Centre

SARS-CoV2

Pre-Clinical

VLP

Unknown

Doherty Institute

SARS-CoV2

Pre-Clinical

VLP

OSIVAX

SARS-CoV1
SARS-CoV2

Pre-Clinical

VLP

eVLP

ARTES Biotechnology

SARS-CoV2

Pre-Clinical

malaria

VLP

VLPs peptides/whole virus

Univ. of Sao Paulo

SARS-CoV2

Pre-Clinical

2. COVID-19 Guidance and information collection on the new mutant variants of the SARS-CoV-2 (2019nCoV) virus

- COVID-19 (SARS-CoV-2): information about the new virus variant
- New SARS-COV-2 variant: information and risk assessment
- Central Alerting System (CAS) alert
- New variant clustering in households analysis (ONS)
- SARS-CoV-2 lateral flow antigen tests: evaluation of VUI-202012/01
- WTO: Statement of the WHO Working Group on COVID-19 Animal Models (WHO-COM) about the UK and South African SARS-CoV-2 new variants.
- EMA guidance for COVID-19 vaccine
- Investigation of novel SARS-CoV-2 variant: Variant of Concern 202012/01
• Investigation of novel SARS-CoV-2 variant: 202012/01. Technical briefing 6
• Investigation of novel SARS-CoV-2 variant: 202012/01. Technical briefing 5
• Investigation of novel SARS-CoV-2 variant: 202012/01. Technical briefing 4
• Investigation of novel SARS-CoV-2 variant: 202012/01. Technical briefing 3
• Investigation of novel SARS-CoV-2 variant: 202012/01. Technical briefing 2
• Investigation of novel SARS-CoV-2 variant: 202012/01. Technical briefing 1

New variant of SARS-COV-2 (2019nCOV) B.1.1.7 lineage spreaded in UK

The world is in midst of the COVID-19 pandemic. Recently a novel SARS-COV-2 (2019nCOV) lineage, the B.1.1.7 lineage, with serials of site mutation, shows stronger infection ability in the UK. The SARS-COV-2 B.1.1.7 lineage carries a larger than a usual number of coronavirus genetic changes.

Extended Reading: Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations

Relative products collection:
GeneMedi products for New variant of SARS-COV-2 (2019nCOV) UK B.1.1.7 lineage

New variant of SARS-COV-2 (2019nCOV) 501Y.V2 lineage(B.1.351) spreaded in South African SARS-CoV-2

The South African variant is characterized by eight lineage-defining mutations in the spike protein including three key residues in the receptor binding domain (K417N, E484K and N501Y) and is referred to as lineage 501Y.V2.

Extended Reading: Alert Notification: New SARS-CoV-2 variant with multiple spike protein mutations

Relative products collection:
GeneMedi products for New variant of SARS-COV-2 (2019nCOV) South Africa 501Y.V2 lineage(B.1.351)

3. COVID-19 News and announcements collection on the new mutant variants of the SARS-CoV-2 (2019nCoV) virus

- PHE investigating a novel variant of COVID-19
- Rapid evaluation confirms lateral flow devices effective in detecting new COVID-19 variant
- Confirmed cases of COVID-19 variant from South Africa identified in UK
- Statement from Chief Medical Officer, Professor Chris Whitty, about new strain of COVID-19
- NERVTAG statements on COVID-19 (SARS-CoV-2)
• NERVTAG/SPI-M Extraordinary meetingon SARS-CoV-2 variant of concern 202012/01 (variant B.1.1.7)
• NERVTAG meetingon SARS-CoV-2 variant under investigation VUI-202012/01
• CPR as an AGP - Evidence review and NERVTAG consensus

4. About COVID-19 Pandemic and SARS-CoV-2 Vaccine

Coronavirus Disease 2019 (COVID-19) is a novel viral pneumonia caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). First discovered in Wuhan, a city in Hubei province of China, COVID-19 has already broken out throughout the world and posed a great threat to the public health, especially in Europe and North America now. Additionally, person-to-person transmission of COVID-19 disease is reported to be extremely rapid [158-160]. To date, more than one million cases were infected with COVID-19 and over 55,000 deaths occurred. Therefore, it is really urgent and noteworthy to develop the vaccines specific to COVID-19/SARS-CoV-2.

Belonging to the Betacoronavirus genus family, SARS-CoV-2 is 60～200nm in diameter and encapsidates a large positive-sense, single-stranded RNA virus (26-32kb) with many spikes on the virus capsid (Fig. 17A). The RNA genome of SARS-CoV-2 encodes several accessory proteins and structural proteins, such as nucleocapsid (N) protein, envelope (E) protein, membrane (M) protein, and spike (S) protein (Fig. 10B). Although the detailed mechanism of SARS-CoV-2 infection has not been clearly illuminated, several studies demonstrated that SARS-CoV-2 enters human cells via utilizing spike (S) protein to bind to the angiotensin converting enzyme (ACE2) on the surface of target cell [161, 162]. Picture loading failed.
Figure S1. SARS-CoV-2 capsid structure and genome map. (A) Three-dimensional structure diagram of SARS-CoV-2. (B) Genome organization of SARS-CoV-2 [158]. ORF: open reading frame. E: envelope. M: membrane. N: nucleocapsid. HR1: heptad repeat 1. HR2: heptad repeat 2. SP: signal peptide. NTD: N-terminal domain. RBD: receptor binding domain. S: spike. S1: subunit 1. S2: subunit 2. TM: transmembrane domain.

Since the genome sequences of SARS-CoV were discovered and reported (https://www.gisaid.org/CoV2020/), a large number of pharmaceutical enterprises and research organizations are sparing all efforts to the vaccine development. Different companies utilize different targets and antigen epitopes. Some of the advances are listed in the following Table 10 (from WHO), and most of them focus on viral vector-based vaccines (replicating or non-replicating viral vector-based vaccines), recombinant protein (Spike), and nucleic acid-based vaccines. To date, two COVID-19 vaccines have entered Phase I clinical testing to assess the safety and potency of vaccines. One is mRNA-1273, was developed by Moderna Therapeutics, encoding a prefusion-stabilized form of Spike (S) protein [163] (https://www.nature.com/articles/d41587-020-00005-z). Another vaccine is recombinant protein of SARS-CoV-2 antigen, developed by Chinese Academy of Military Sciences, Institute of Military Medicine. It was predicted that these vaccines can be applied in clinics in a large scale as early as 2021 if they can successfully pass the clinical testing. Although there is a long way for theses vaccines to be applied for prevention and therapy of COVID-19, they indeed bring great hope and light to people all over the world.

References

1. 2 Korber, B. et al. Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. bioRxiv Preprint., doi:10.1101/2020.04.29.069054 (2020). 2. Investigation of novel SARS-COV-2 variant. Public health England. 3. European Centre for Disease Prevention and Control. Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom – 20 December 2020.ECDC: Stockholm; 2020. 4. Li, G. & De Clercq, E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews Drug Discovery, doi:10.1038/d41573-020-00016-0 (2020). 5. Haque, A. & Pant, A. B. Efforts at COVID-19 Vaccine Development: Challenges and Successes. Vaccines 8, doi:10.3390/vaccines8040739 (2020). 6. Dong, Y. et al. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy 5, doi:10.1038/s41392-020-00352-y (2020). 7. Andrew Rambaut1, N. L., Oliver Pybus, Wendy Barclay, Jeff Barrett5, Alesandro Carabelli6, Tom Connor, Tom Peacock, David L Robertson8, Erik Volz, . Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. https://virological.org/ (2020). 8. Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom. European Centre for Disease Prevention and Control: Publications & data. 9. Zhang, L. et al. SARS-CoV-2 RNA reverse-transcribed and integrated into the human genome. bioRxiv Preprint. , doi:10.1101/2020.12.12.422516 (2020).

Products & solutions & information collection of COVID-19 vaccines, new variants of SARS-CoV-2 and efficacy evaluation solutions.

Challenge of COVID-19 vaccine discovery & development: to meet accumulated mutating of SARS-CoV-2 and a long-term viral genome transcrption

1. GeneMedi information and products collection of SARS-COV-2 (2019nCOV) UK B.1.1.7 lineage and South Africa 501Y.V2 lineage and Brazilian P.1 lineage(B.1.1.28.1)

GeneMedi pseudotyped virus (pseudovirus) of SARS-COV-2 (2019nCOV) B.1.1.7 lineage

GeneMedi pseudotyped virus (pseudovirus) of SARS-COV-2 (2019nCOV) 501Y.V2 lineage

GeneMedi pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) P.1 lineage(B.1.1.28.1, Brazilian variant)

SARS-COV-2 (2019nCOV) B.1.1.7 lineage & 501Y.V2 lineage(B.1.351) & P.1 lineage (B.1.1.28.1, Brazilian variant) of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies

GeneMedi codon-optimized spike mammalian expression vector for SARS-COV-2 (2019nCOV) B.1.1.7 lineage

GeneMedi codon-optimized spike mammalian expression vector for SARS-COV-2 (2019nCOV) South Africa 501Y.V2 lineage(B.1.351).

GeneMedi codon-optimized spike mammalian expression vector for SARS-COV-2 (2019nCOV) - P.1 lineage(B.1.1.28.1, Brazilian variant)

2. Multiple variants of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies

3. Multi-VariantsTM SARS-CoV2 (wildtype, D614G, N501Y, E484K, B.1.1.7 lineage, 501Y.V2 lineage, and so on) Pseudotype virus-Based Neutralization Assay System for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies (Lentiviral pseudovirus)

4. Codon-optimized mammalian expression vector for SARS-COV-2 (2019nCOV) spike wide type & mutant variants (D614G, N501Y, E484K, B.1.1.7 lineage, 501Y.V2 lineage, and so on)

Codon-optimized viral particle (Adenovirus, Lentivirus, AAV) for SARS-COV-2 (2019nCOV) spike wide type & mutant variants (D614G, N501Y, E484K, B.1.1.7 lineage, 501Y.V2 lineage, and so on)

5. 293T-ACE2 stable cell line & human ACE2 expression vectors: Effector cell of pseudotype virus-Based Neutralization Assay System for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies (Lentiviral pseudovirus)

6. Validated SARS-CoV-2 neutralizing antibodies-benchmark COVID-19 neutralizing antibodies.

1. Landscape of global COVID-19 vaccine candidates development

2. COVID-19 Guidance and information collection on the new mutant variants of the SARS-CoV-2 (2019nCoV) virus

New variant of SARS-COV-2 (2019nCOV) B.1.1.7 lineage spreaded in UK

New variant of SARS-COV-2 (2019nCOV) 501Y.V2 lineage(B.1.351) spreaded in South African SARS-CoV-2

3. COVID-19 News and announcements collection on the new mutant variants of the SARS-CoV-2 (2019nCoV) virus

4. About COVID-19 Pandemic and SARS-CoV-2 Vaccine

References

About GeneMedi

3. Multi-Variants^TM SARS-CoV2 (wildtype, D614G, N501Y, E484K, B.1.1.7 lineage, 501Y.V2 lineage, and so on) Pseudotype virus-Based Neutralization Assay System for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies (Lentiviral pseudovirus)